Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Temozolomide in Treating Patients With Brain Metastases Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Temozolomide in Treating Patients With Brain Metastases conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Temozolomide in Treating Patients With Brain Metastases Clinical research trials and Temozolomide in Treating Patients With Brain Metastases health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Temozolomide in Treating Patients With Brain Metastases. Temozolomide in Treating Patients With Brain Metastases Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Temozolomide in Treating Patients With Brain Metastases clinical trial. Test subjects typically receive the most expert healthcare available for their Temozolomide in Treating Patients With Brain Metastases condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.

Home > "T" Clinical Trials Conditions > Temozolomide in Treating Patients With Brain Metastases

Temozolomide in Treating Patients With Brain Metastases



Temozolomide in Treating Patients With Brain Metastases

For Condition: brain metastases
Status: No longer recruiting
Sponsor(s): Duke Comprehensive Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have brain metastases.
Details: OBJECTIVES: - Determine the activity of temozolomide in patients with brain metastases. - Determine the toxicity of this treatment in these patients. OUTLINE: Patients are stratified according to type of primary cancer (lung carcinoma vs breast carcinoma vs malignant melanoma vs renal cell carcinoma vs colorectal carcinoma vs other). Patients receive oral temozolomide daily on days 1-7 and 15-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 180 patients (30 per stratum) will be accrued for this study.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Metastatic lesions to the brain - Must not require immediate radiotherapy - If received prior radiotherapy, must have progressive disease - Evaluable disease by CT scan or MRI - Neurologically stable PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 70-100% Life expectancy: - More than 12 weeks Hematopoietic: - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 10 g/dL Hepatic: - Bilirubin less than 1.5 times upper limit of normal (ULN) - SGOT or SGPT less than 2.5 times ULN - Alkaline phosphatase less than 2 times ULN Renal: - Blood urea nitrogen less than 1.5 times ULN - Creatinine less than 1.5 times ULN Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No other concurrent nonmalignant systemic disease - No acute infection requiring treatment with IV antibiotics - HIV negative - No frequent vomiting or medical condition that would preclude oral medication administration (e.g., partial bowel obstruction, inability to swallow) PRIOR CONCURRENT THERAPY: Biologic therapy: - No concurrent hematopoietic growth factors, including epoetin alfa - No other concurrent biologic therapy Chemotherapy: - At least 4 weeks since prior chemotherapy, unless evidence of disease progression - No other concurrent chemotherapy Endocrine therapy: - Concurrent corticosteroids allowed if nonincreasing dose for at least 1 week prior to study Radiotherapy: - See Disease Characteristics - At least 4 weeks since prior radiotherapy to the brain, unless evidence of disease progression - No concurrent radiotherapy Surgery: - At least 3 weeks since prior surgery, unless evidence of disease progression, and recovered Other: - No other concurrent investigational drugs
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
HenryFriedman,  Study Chair,  Duke Comprehensive Cancer Center

Duke Comprehensive Cancer Center
Durham,  North Carolina,  27710
United States
 


Additional Information:
Study ID Numbers:  CDR0000067934;  NCI-G00-1798,DUMC-2114-02-12R3
Study Start Date: 
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005954

Other Brain Metastases Studies:
1. Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases

2. Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases

3. Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases

4. Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer Involving the Central Nervous System

5. Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases

Related Studies:

Other brain metastases Clinical Trials
Other North Carolina Clinical Trials
Other Durham Clinical Trials

Temozolomide in Treating Patients With Brain Metastases
Modify your Search

  Other brain metastases Clinical Trials
  Other North Carolina Clinical Trials
  Other Durham Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103